AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01037647 — intervention group
Intervention type: OTHER
Intervention: Hyperinsulinemic euglycemic glucose clamp
Description: Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
Study NCT01220947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: Copegus 1000 mg or 1200 mg po daily for 24 weeks.
Study NCT01220947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus
Description: Copegus 1000 mg or 1200 mg po daily for 24 weeks.
Study NCT01220947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir 50 mg BID
Study NCT01220947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir 100 mg BID
Study NCT01220947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir 200 mg BID
Study NCT01220947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Pegasys 180 microgram sc qw
Study NCT01220947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: Pegasys 180 microgram sc qw
Study NCT01220947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg
Study NCT03012958 — intervention group
Intervention type: OTHER
Intervention: Lung clearance index (LCI)
Description: LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
Study NCT01288248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway laryngeal mask classic
Description: This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.~The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned
Study NCT01288248 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal tube
Description: This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.~The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age.
Study NCT02536352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prenatal vitamin-mineral containing 3 mg fluoride
Description: Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
Study NCT02536352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prenatal vitamin-mineral containing 0 mg fluoride
Description: Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
Study NCT03869866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular
Study NCT00493636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
Study NCT00493636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
Study NCT00526994 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: universal education
Description: receives referral information
Study NCT02498145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarette
Description: Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
Study NCT00493636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
Study NCT00493636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
Study NCT00493636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
Study NCT00493636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
Study NCT00854217 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: acute normovolemic hemodilution
Study NCT03352453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel pre-filled syringes for weekly IV injections.
Study NCT03352453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study NCT00346502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% betulinic acid ointment
Study NCT00346502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA
Description: 20% Betulinic Acid Ointment
Study NCT02368912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707 single dose of dose levels 1 -7
Description: Oral, dose escalation
Study NCT02368912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo single dose of dose levels 1-7
Description: Oral, dose escalation, healthy young male
Study NCT02368912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707 single dose fasted
Description: Oral, healthy young male
Study NCT02368912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707 single dose fed
Description: Oral, healthy young male
Study NCT02368912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707 multiple dose of dose levels 1-4
Description: Oral, multiple dose escalation, healthy elderly male
Study NCT02368912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo multiple dose of dose levels 1-4
Description: Oral, multiple dose escalation, healthy elderly male
Study NCT02368912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707 multiple dose of dose levels 1-2
Description: Oral, multiple dose escalation, healthy pre-menopausal female
Study NCT02368912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo multiple dose of dose levels 1-2
Description: Oral, multiple dose escalation, healthy pre-menopausal female
Study NCT02368912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707 parallel multiple dose of dose levels 1-3
Description: Oral, multiple dose, healthy pre-menopausal female
Study NCT02368912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo parallel multiple dose
Description: Oral, dose escalation, healthy pre-menopausal female
Study NCT00161577 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac
Description: Intravenous ketorolac every 6 hours for 24 hours
Study NCT00161577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT00994734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: home administration of mifepristone
Study NCT03215927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept 125mg subcutaneous weekly
Study NCT03215927 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03724981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide Pen
Description: Injected on a practice pad.
Study NCT03724981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen
Description: Injected on a practice pad.
Study NCT01589744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)
Description: The haemostatic intra-uterine suction-cup is introduced in uterus and a depressure in this device is applied. This medical device is used for 5 minutes at maximum.
Study NCT03874247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pelubiprofen 45mg
Description: bid for 3 days after meal
Study NCT03874247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pelubiprofen placebo
Description: bid for 3 days after meal
Study NCT01577056 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil capsule
Description: 4g Omega capsule for 12 weeks
Study NCT01577056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMG Coenzyme reductase
Description: All FH subjects are on standard statin treatment during study period
Study NCT00005094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally
Study NCT02498145 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-nicotine e-cigarette
Description: Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
Study NCT03897699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively.
Study NCT02962414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus, 2mg dispersible tablets
Study NCT03817463 — intervention group
Intervention type: DRUG
Intervention: Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Description: Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Study NCT03817463 — intervention group
Intervention type: DRUG
Intervention: Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
Description: Dipeptidyl peptidase-4 (DPP-4) inhibitor
Study NCT00005094 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02813564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment & Video-game INtervention Solutions (CAVINS)
Description: This is a computerized video-game like intervention. The participants will exercise/strengthen the cognitive (mental) deficits that may be responsible for symptom profiles such as socialization impairments, academic disabilities, and repetitive behaviour for several weeks. This program will stimulate communication between brain regions that make up an information processing neural network in order to promote proper network development.
Study NCT00429104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: 4 mg/kg IV Over 90 Minutes
Study NCT00429104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/m\^2 Subcutaneously
Study NCT01169974 — intervention group
Intervention type: OTHER
Intervention: tourniquet ischemia
Description: Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 \& 3 minutes
Study NCT00937612 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
Study NCT02707991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Case Management
Description: Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
Study NCT03897699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing
Description: MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
Study NCT03897699 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mindful Breathing
Description: MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
Study NCT03897699 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Weak electrical current (\~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.
Study NCT04495621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1611
Description: MEN1611 oral dose administered twice daily for a continuous 28-day cycle.
Study NCT04495621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab solution for infusion administered weekly via IV infusion.
Study NCT01733771 — intervention group
Intervention type: OTHER
Intervention: CAM treatments
Description: CAM treatments last 10-30 minutes
Study NCT03059823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: Anti-PD-1 monoclonal antibody
Study NCT03119194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BIA 9-1067
Description: 1 × 100 mg capsule, Oral
Study NCT01437046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Doxazosin 16mg/day
Study NCT01437046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04655274 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Quality of Vision questionnaire
Description: The Quality of Vision questionnaire rates glare, halos, starbursts, hazy/blurred/double vision, distortion, focusing difficulties, fluctuation, and depth perception conditions.
Study NCT00699621 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelets
Description: Four units of fresh platelets will be infused immediately
Study NCT02226055 — intervention group
Intervention type: DEVICE
Intervention: Arterial Stiffness Assessment
Description: The following will be measured: brachial systolic and diastolic bp, heart rate, mean arterial bp, pulse pressure, brachial augmentation index (difference between the amplitudes of the late (backward) systolic wave (P2) and the early (forward) systolic wave (P1) over the pulse pressure x 100), central augmentation, ejection duration of the left ventricle, return time (time of the pulse wave travelling from aortic root to the bifurcation and back), aortic pulse wave velocity ( velocity of the pulse wave in the aorta), central systolic bp, central pulse pressure and diastolic reflection area (provides information about the quality of diastolic filling in the coronary arteries).~We will perform an arterial age assessment. Patients are given a feedback form with their results to give to their general. Those with increased arterial stiffness will be tested for serum calcium and phosphate levels, and audited to ensure that a statin is commenced if not contraindicated.
Study NCT03222050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction technique
Study NCT01634815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Edge
Description: measuring blood lactate
Study NCT01705821 — intervention group
Intervention type: DEVICE
Intervention: Use of force sensing surgical curette
Description: Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
Study NCT01705821 — intervention group
Intervention type: PROCEDURE
Intervention: Removal of pituitary tumor using modified curette
Study NCT00804830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
Study NCT00774618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resection with or without plate fixation
Description: Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
Study NCT01486251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles.
Study NCT02396901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Direct Therapy
Description: Goal Direct Therapy - in this group patients will receive the standard treatment according with institutional protocol.
Study NCT01078012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trained counselling
Study NCT02818322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedical monitoring ( T)
Study NCT02818322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classic monitoring
Study NCT02818322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: classic monitoring
Study NCT05553002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deneroll cervical extension traction
Description: Participants will lie flat on their back on the ground with their legs extended and arms by their sides. The denneroll will placed on the ground and positioned in the posterior aspect of the neck depending on the area to be addressed . The apex of the Denneroll orthotic will be placed in one of three regions based on lateral cervical radiographic displacements:~1. In the upper cervical region (C2-C4) region.~2. The apex of the Denneroll orthotic is placed in the mid-cervical region (C4-C6) region.~3. The apex of the Denneroll orthotic is placed in the upper thoracic lower-cervical region (C6-T1) region.
Study NCT05553002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional treatment
Description: The participants will receive hot packs (15 minutes) and TENS therapy .During TENS application. Patients will be asked to adopt a prone position. The TENS therapy will be delivered at the lumbosacral region for 20 min. The frequency will set to 80 Hz and pulse width to 50 µs due to its analgesic effect . These conventional treatments will be repeated three times per week over the course of 10 weeks for 30 total sessions
Study NCT05553002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: The participants will receive hot packs (15 minutes) and TENS therapy .During TENS application. Patients will be asked to adopt a prone position. The TENS therapy will be delivered at the lumbosacral region for 20 min. The frequency will set to 80 Hz and pulse width to 50 µs due to its analgesic effect . These conventional treatments will be repeated three times per week over the course of 10 weeks for 30 total sessions